ALNY - Alnylam Pharmaceuticals, Inc.

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Alnylam posts Q4 topline miss; pushes back key data readout
• Alnylam Pharmaceuticals Non-GAAP EPS of -$0.77 in-line, revenue of $439.72M misses by $2.58M
• Alnylam Pharmaceuticals Q4 2023 Earnings Preview
• Investors growing more bullish on SMID cap biotech stocks
• Regeneron eyes Wegovy combo to improve quality of weight loss
• Alnylam reports preliminary Q4 global net product revenues
• U.S. strong buy ideas for the next 12 months – according to Citi
• Biotechs post record gains in November amid improving outlook
• Alnylam reports positive Phase 2 data for hypertension drug
• Alnylam Pharmaceuticals beats Q3 top and bottom line estimates; updates FY23 outlook
• Alnylam Pharmaceuticals Q3 2023 Earnings Preview
• Alnylam downgraded at Oppenheimer ahead of key data readout
• Alnylam sends Arbutus lower after FDA snub for amyloidosis drug
• Alnylam U.S. label expansion for amyloidosis drug denied
• Ionis, AbbVie, Alnylam draw bullish views at Raymond James
• Citi says concerns over FDA approval of Alnylam drug are "overdone"
• Alnylam stock falls after FDA panel questions drug's effectiveness
• Alnylam wins FDA panel backing additional Onpattro indications
• Alnylam stock trading halted as FDA AdCom meets on amyloidosis drug
• Alnylam amyloidosis drug led to “small” benefits in Phase 3 trial: FDA